Reduction in Levels of Plasma Vascular Endothelial Growth Factor-A and Improvement in Hydrocele Patients by Targeting Endosymbiotic Wolbachia sp in Wuchereria bancrofti with Doxycycline

  • Alexander Y. Debrah
  • , Sabine Mand
  • , Yeboah Marfo-Debrekyei
  • , Linda Batsa
  • , Kenneth Pfarr
  • , Bernard Lawson
  • , Mark Taylor
  • , Ohene Adjei
  • , Achim Hoerauf

Research output: Contribution to journalArticlepeer-review

54 Citations (Scopus)

Abstract

The treatment for hydrocele is expensive, invasive surgery-hydrocelectomy. A drug that could prevent or improve this condition could replace or supplement hydrocelectomy. In Ghana, 42 hydrocele patients participated in a double-blind, placebo-controlled trial of a six-week regimen of doxycycline, 200 mg/day. Four months after doxycycline treatment. patients received 150 mu g/kg of ivermectin and 400 mg of albendazole, which is used for mass chemotherapy in this area. Patients were monitored for levels of Wolbachia sp., microfilaremia, antigenemia, plasma levels of vascular endothelial growth factor-A (VEGF-A) and stage/size of the hydrocele. Wolbachia sp. loads/microfilaria, microfilaremia, and antigenemia were significantly reduced in the doxycycline-treated patients compared with the placebo group. The mean plasma levels of VEGF-A were decreased significantly in the doxycycline-treated patients who had active infection. This finding preceded the reduction of the stage of hydrocele. A six-week regimen of dox

Original languageEnglish
Pages (from-to)956-963
Number of pages8
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume80
Issue number6
DOIs
Publication statusPublished - 1 Jun 2009

Fingerprint

Dive into the research topics of 'Reduction in Levels of Plasma Vascular Endothelial Growth Factor-A and Improvement in Hydrocele Patients by Targeting Endosymbiotic Wolbachia sp in Wuchereria bancrofti with Doxycycline'. Together they form a unique fingerprint.

Cite this